Cost-Utility of Sunitinib (SU) for Treatment of Advanced or Metastatic Pancreatic Neuroendocrine Tumors (pNET) in Scotland and Wales

被引：0
|
作者：
Johns, A. [1 ]
Eatock, M. [2 ]
Johal, S. [3 ]
机构：
[1] Pfizer UK, Tadworth, England
[2] No Ireland Canc Ctr, Belfast, Antrim, North Ireland
[3] RTI Hlth Solut, Sheffield, S Yorkshire, England
来源：
NEUROENDOCRINOLOGY | 2012年 / 96卷
关键词：
sunitinib; overall survival; cost-utility; pancreatic net;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：38 / 38
页数：1
相关论文
共 47 条
  • [41] An updated cost-effectiveness analysis of pazopanib versus sunitinib as first-line treatment for locally advanced or metastatic renal cell carcinoma in Italy
    Capri, Stefano
    Porta, Camillo
    Condorelli, Claudia
    Premoli, Eleonora
    Khare, Ankur
    Kalra, Manik
    Modi, Niraj
    Ratto, Barbara
    JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (12) : 1579 - 1587
  • [42] Cost-Effectiveness Analysis of Sunitinib versus Interferon-Alfa for First-Line Treatment of Advanced and/or Metastatic Renal Cell Carcinoma in Singapore
    Pruis, Sil-ling
    Aziz, Mohamed Ismail Abdul
    Pearce, Fiona
    Tan, Min Han
    Wu, David Bin-Chia
    Ng, Kwong
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2019, 35 (02) : 126 - 133
  • [43] Cost-Utility Analysis of Pembrolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer With Different PD-L1 Expression Levels
    Weng, Xiuhua
    Luo, Shaohong
    Lin, Shen
    Zhong, Lixian
    Li, Meiyue
    Xin, Rao
    Huang, Pinfang
    Xu, Xiongwei
    ONCOLOGY RESEARCH, 2020, 28 (02) : 117 - 125
  • [44] Observational Study in a Real-World Setting of Targeted Therapy in the Systemic Treatment of Progressive Unresectable or Metastatic Well-Differentiated Pancreatic Neuroendocrine Tumors (pNETs) in France: OPALINE Study
    Denis Smith
    Côme Lepage
    Eric Vicaut
    Sophie Dominguez
    Romain Coriat
    Olivier Dubreuil
    Thierry Lecomte
    Eric Baudin
    Laurence Venat Bouvet
    Emmanuelle Samalin
    Alexandre Santos
    Odile Borie
    Ségolène Bisot-Locard
    Bernard Goichot
    Catherine Lombard-Bohas
    Advances in Therapy, 2022, 39 : 2731 - 2748
  • [45] Observational Study in a Real-World Setting of Targeted Therapy in the Systemic Treatment of Progressive Unresectable or Metastatic Well-Differentiated Pancreatic Neuroendocrine Tumors (pNETs) in France: OPALINE Study
    Smith, Denis
    Lepage, Come
    Vicaut, Eric
    Dominguez, Sophie
    Coriat, Romain
    Dubreuil, Olivier
    Lecomte, Thierry
    Baudin, Eric
    Bouvet, Laurence Venat
    Samalin, Emmanuelle
    Santos, Alexandre
    Borie, Odile
    Bisot-Locard, Segolene
    Goichot, Bernard
    Lombard-Bohas, Catherine
    ADVANCES IN THERAPY, 2022, 39 (06) : 2731 - 2748
  • [46] Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vsobservation with predefined second-line treatment after cisplatin–gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study
    Isabelle Borget
    Maurice Pérol
    David Pérol
    Armelle Lavolé
    Laurent Greillier
    Pascal Dô
    Virginie Westeel
    Jacky Crequit
    Hervé Léna
    Isabelle Monnet
    Hervé Le Caer
    Pierre Fournel
    Lionel Falchero
    Michel Poudenx
    Fabien Vaylet
    Sylvie Chabaud
    Alain Vergnenegre
    Gérard Zalcman
    Christos Chouaïd
    BMC Cancer, 14
  • [47] Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study
    Borget, Isabelle
    Perol, Maurice
    Perol, David
    Lavole, Armelle
    Greillier, Laurent
    Do, Pascal
    Westeel, Virginie
    Crequit, Jacky
    Lena, Herve
    Monnet, Isabelle
    Le Caer, Herve
    Fournel, Pierre
    Falchero, Lionel
    Poudenx, Michel
    Vaylet, Fabien
    Chabaud, Sylvie
    Vergnenegre, Alain
    Zalcman, Gerard
    Chouaid, Christos
    BMC CANCER, 2014, 14
12345